| abstract |
methods and compositions for modifying type i ifn signaling pathways in an individual comprising administering a cationic lipid to the individual are provided. cationic lipids comprise 1,2-dioleoyl-3-trimethylammonium propane (dotap), n-1- (2,3-dioleoyloxy) -propyl-n, n, n-trimethyl ammonium (dotma), 1,2- dioleoil-sn-glicero-3-ethylphosfocolina (doepc), enantiomers and their combinations. the compositions may further comprise one or more antigenic components, where those components are autologous or non-autologous. |